GB Pharma Corporation
Update：2026/11/10
Industries
Main Industry
Health Care
Main Product/Service
GB Pharma Corporation operates and manages the oh care® brand, applying cutting-edge scientific research achievements, such as the P113 antibacterial peptide, to the development of oral care, baby care, and skincare products to create a scientifically validated, safe, and effective daily health experience.
The content above was translated by Ai
Founded Year
2020
Unified Business No.
28114877
Status
Active
Number of Employees
15
Total Paid-in
Capital
49,780,000 (NT$)
Location of Company
Taiwan
, Hsinchu County
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Established in 1984, General Biologicals Corporation is a professional GMP manufacturing company that produces Class III medical diagnostic reagents. From the most basic raw material production to clinical testing services, the company has established a complete biomedical value supply chain. The quality and innovative technology of the various products developed and manufactured by the company have been recognized and affirmed by government reviews, winning numerous biotechnology awards. In 2014, the company officially expanded into the field of new drug development. In 2022, it established its subsidiary, Puyan Biotech Co., Ltd., and transferred its proprietary brand of P113+ antibacterial peptide, along with its new drug development plans and other projects, to this subsidiary.
The content above was translated by Ai
